C ongenital heart defects (CHDs) are diagnosed in Ϸ1 in 100 to 150 newborns. [1] [2] [3] The global impact of CHDs on mortality in the United States in recent years, however, is unclear. Surgical series on specific CHDs from selected tertiary centers 4 -8 have documented improvements in survival for children with CHDs. Such studies, however, lack data on persons who did not undergo or did not survive to surgery. The extent to which findings from selected medical centers can be generalized to the entire US population is unclear. Researchers have used a variety of other sources, including death certificates, to evaluate the contribution of CHDs to mortality 9 in the US population. No data after 1988 are available, however.
We present trends and patterns of mortality from CHDs in the United States for 1979 to 1997. We studied death certificates to determine (1) the extent to which CHDs contributed to mortality at different ages and how that changed over time, (2) which heart defects contributed most to mortality, and (3) whether patterns of mortality differed between races.
Methods
Since 1968, the National Center for Health Statistics has annually compiled data from all death certificates filed in the United States and has made these data available on its Multiple-Cause Mortality Files. These files include demographic and geographic information on the decedent, International Classification of Disease (ICD) codes for the underlying cause of death, and up to 20 conditions listed (after 1979) on the death certificate. The ICD, Ninth Revision (ICD-9), was implemented in 1978. Details on these files and the quality assurance of the data have been published. 10 From these multiple-cause mortality files, we determined the number of deaths for which a CHD was noted in the death certificate for 1979 to 1997. We identified records that contained ICD-9 codes 745.0 to 747.4 in the fields for underlying or contributing causes of death. The selected range of codes includes congenital anomalies of the heart and great vessels and excludes anomalies of the peripheral circulatory system. We defined as deaths associated with a CHD the records that had any mention of such codes as a cause of death, and as deaths due to a CHD the subset for which 1 such code was listed as the underlying cause of death.
We calculated the age-specific annual death rates as the number of deaths per 100 000 population. We used 1970 We used , 1980 We used , and 1990 national census data to calculate intercensal population by age, sex, and racial groups to estimate the appropriate denominators by such groups. For infant mortality, we used the number of births as denominator. We examined the age-specific death rates for the following groups: Ͻ1 year (infants), 1 to 4 years, 5 to 9 years, and then on in 5-year increments up to age 64 years, and 1 group for persons age Ն65 years. We examined 3 racial/ethnic groups: whites, blacks, and others. We studied the following specific groups of heart defects: outflow tract defects (ICD-9-CM codes 745.0 to 745.2), including common truncus arteriosus (745.0), transposition of the great arteries (745.1), and tetralogy of Fallot (745.2); septal defects (745.4 to 745.9, with the exclusion of 745.0 to 745.2), including ventricular (745.4), atrial (745.5), and atrioventricular septal defects (AV canal) (745.6); patent ductus arteriosus (747.0); coarctation of the aorta (747.1); aortic valve anomalies (746.3 to 746.4); pulmonary valve anomalies (746.0); hypoplastic left heart syndrome (HLHS) (746.7); and single ventricle (745.3). We excluded cases of patent ductus arteriosus among infants Ͻ37 gestational weeks or weighing Ͻ2500 g.
We calculated rates for each year and for 3-year intervals. We computed the average annual percentage change in death rates over the study period as the yearly percent change that, compounded over the total period, would generate the total change. We evaluated time trends using the Cochran-Armitage test 11, 12 implemented in SAS statistical software (SAS Corp).
Death rates included only deaths for which a CHD was the underlying cause of death. We calculated age at death as an indirect estimate of the survival of persons with CHDs, and for that purpose, we used records with any mention of a CHD (ICD-9 codes 745.0 to 747.4). Age-at-death estimates were truncated at age group 65 to 70 years.
Results

Impact of Heart Defects on Mortality
The multiple-cause mortality files for all ages for 1979 to 1997 contain records for Ϸ40.6 million deaths. We identified 124 832 deaths (0.31%) associated with a CHD. In 76% of these deaths (94 249, or 0.23% of all), the CHD was the underlying cause, ie, the death was due to a CHD. Mortality due to a CHD was highest among infants and children, then declined rapidly and was stable for persons 15 to 65 years old ( Figure 1 ). The mortality due to CHDs was on average 24% higher among males than among females (Figure 1 , note the logarithmic scale; Table 1 ).
From 1979 through 1997, mortality due to CHDs declined 39.4%, from 2.54 to 1.54 per 100 000, or 1.9% per year ( Figure 2 ). Deaths associated with CHDs declined from an annual average of 7169 in 1979 to 1981 to an annual average of 5822 in 1995 to 1997. Approximately half of all deaths associated with or due to a CHD occurred in infancy. In 1995 to 1997, 1 in 10 infant deaths (9.8%) were associated with a CHD, and 1 in 13 infant deaths (7.4%) were due to a CHD (data not shown).
Mortality from CHDs decreased in nearly all age groups, but particularly among children Ͻ5 years old (Table 1) . For example, the number of deaths among infants in 1995 to 1997 was half that recorded in 1979 to 1981. Among infants, mortality due to CHDs declined gradually, an average 2.7% per year (38.7% total), during the study period (Table 1) . Among children 1 to 4 years old, the decline was even greater, 4.5% per year (56.9% total). Mortality was higher among boys than among girls in both age groups (Table 1 ).
Specific Types of Heart Defects
A specific type of heart anomaly was recorded in Ͼ60% of infant deaths due to CHDs (Table 1) . Mortality varied by type of defect, and for several defects it changed over time. HLHS was associated with the highest mortality among infants, Ϸ15 per 100 000, remaining high despite a slight decrease over the study period. Among children age 1 to 4 years, mortality from HLHS increased (Table 1 ). Other major causes of death were outflow tract defects, defects of septal closure, and coarctation of the aorta. The mortality from most of these defects declined gradually during the study period ( Figure 3 ). These trends among children age 1 to 4 years were generally similar to those among infants, but mortality was much lower (Table 1) .
Survival: Trends in Median Age at Death
The age at death from CHDs increased over the study period for most defects ( Table 2 ). The increase in age at death was usually more notable for the 75th percentile than for the median (50th percentile). We presented data on several major defects: transposition of the great arteries and tetralogy of Fallot (as examples of serious and relatively common cyanotic heart defects), ventricular septal defects (common defects with usually good prognosis), atrial septal defects (defects with good survival throughout the study period), pulmonary and aortic valve anomalies (common defects with variable prognosis), and HLHS (defect with high mortality). For most anomalies, with the exception of HLHS, the median age at death increased considerably, as did the 75th percen-tile. The median age at death for all CHDs combined increased by months and the 75th percentile by years. For ventricular septal defects, the median age at death increased by 28 years and the 75th percentile by 20 years (Table 2 ).
Racial Disparities
Mortality from CHDs was higher and declined more slowly among blacks than among whites (Table 1 ). In 1995 to 1997, for example, infant mortality was 19% higher among blacks than among whites (68.4 and 55.5 per 100 000, respectively) and declined more slowly (by 2.1% versus 2.7% per year, respectively). Such disparity occurred for most types of heart defects and throughout the study period ( Figure 4 ). In general, the increase in average age at death was more pronounced among whites than among blacks ( Table 2 ). These differences did not seem to decrease. For a number of defects (eg, transposition of the great arteries, tetralogy of Fallot, ventricular septal defects), blacks died at a younger age (often approximately half the age of whites).
Discussion
These national, population-based data show that mortality from CHDs declined Ϸ40% from 1979 through 1997. Most of the decline occurred in children Ͻ5 years old. This age group, however, still experiences the highest mortality from CHDs. Mortality declined for many heart defects, although not equally. For some defects, such as patent ductus arteriosus and coarctation of the aorta, the marked mortality decrease in the early part of the study seems to have leveled off during the last decade. Infant mortality from HLHS has not decreased much since the mid-1980s. The average age at death from this defect almost doubled, however, from 0.4 to 0.7 years, suggesting improved short-term survival.
Not only are people dying at a slower rate from CHDs, but deaths also tend to occur progressively later. Although the median age at death is only an indirect indicator of survival, its increase suggests that, overall, survival has improved for people with a CHD. Such improvements, however, did not seem to accrue equally among whites and blacks. Outcomes among blacks appeared generally worse than among whites, regardless of outcome measure (mortality or age at death) and type of heart defect. Moreover, the gap is not closing. The higher death rates among blacks cannot be explained by higher prevalence, because the prevalence of CHDs may actually be lower than among whites. 2, 13 The causes of these disparities are unknown but could be related to access to health care, rate of complications, or differences in severity of the lesions.
Death rates tended to be higher among boys, particularly during infancy. This can be partially explained by the higher proportion of boys among infants born with serious CHDs such as HLHS, transposition of the great arteries, pulmonary atresia, tricuspid atresia, coarctation of the aorta, and aortic stenosis. 14, 15 The interpretation of our findings must incorporate the limitations and strengths of the study design and analysis. Although many efforts have been made to improve the quality of data on death certificates, the completeness and accuracy of information are still not ideal. Miscoding and misclassification leading to substantial underreporting 16 or overreporting 17 have been shown for some diseases. Death certificates may not be a reliable data source for diseases that have a low case-fatality rate 18 or for which survival is very long. 19 This is not usually the case for CHDs, however. A British study found substantial underreporting of congenital anomalies in stillbirth and neonatal death certificates. 20 Underreporting of heart anomalies was also suggested in a US study, particularly when the affected child died soon after birth. 2, 21 We are unable to estimate the degree of overreporting and underreporting in our data. Nevertheless, time trends and racial comparisons should still be valid, provided that the sensitivity of the system remained the same.
Ideally, to study trends in mortality and survival, the population at risk (persons born with a heart defect) should be identified and followed up over time. Using death certificates instead could lead to spurious results if prevalence or casefatality ratio varies over time. Decreasing prevalence of CHDs at birth could theoretically account for part of the decrease in mortality. Data from the United States are consistent with an increase, however, rather than a decrease, in reported prevalence of CHDs. 3, 22, 23 Thus, decrease in mortality and increase in age at death are mutually consistent and suggest a real increase in survival.
The major strength of the study was the opportunity to assess national trends. The use of death certificates, which record nearly all deaths, enabled us to assess the impact of CHDs on essentially the entire population, including individuals who do not undergo surgery and thus are not reported in surgical series.
The decline in mortality in this study is not explained by a decrease in number of births, which did not occur, or a decrease in birth rates, which declined only slightly, from 15.6/1000 in 1979 to 14.5/1000 in 1997, 24 and which is already incorporated into the computation of infant death rates.
Our findings are consistent with population-based data from the United States and other countries that suggest a significant survival among persons with CHDs. 1, 25 Reduced mortality probably results from improved diagnostic abilities, enhanced surgical techniques, and advances in intensive care over the past 2 decades. Pregnancy termination is unlikely to have contributed in determining overall trends in heart defect mortality, because the proportion of prenatally diagnosed CHDs still appears to be small in the United States. 26 Two further points emerge from these data. First, our findings on racial disparities in mortality suggest that some deaths from CHDs could be preventable. Finding the causes of these disparities will be a crucial step to improve outcomes. Second, the increasing survival of infants and children with CHDs into adolescence and adulthood underscores the need for the healthcare community to prepare for the challenging and often complex needs of adults with CHDs. 27, 28 For those who reach adulthood, reproductive counseling and carefully tailored pregnancy management may help reduce pregnancy complications and improve pregnancy outcomes. A concerted effort of cardiologists and other specialists is needed to successfully face these challenges and further decrease the burden of congenital heart disease.
